全文获取类型
收费全文 | 39753篇 |
免费 | 5887篇 |
国内免费 | 298篇 |
专业分类
耳鼻咽喉 | 875篇 |
儿科学 | 1272篇 |
妇产科学 | 1299篇 |
基础医学 | 4185篇 |
口腔科学 | 994篇 |
临床医学 | 5352篇 |
内科学 | 8575篇 |
皮肤病学 | 946篇 |
神经病学 | 3545篇 |
特种医学 | 1464篇 |
外科学 | 6482篇 |
综合类 | 549篇 |
现状与发展 | 2篇 |
一般理论 | 51篇 |
预防医学 | 4131篇 |
眼科学 | 798篇 |
药学 | 2610篇 |
中国医学 | 25篇 |
肿瘤学 | 2783篇 |
出版年
2023年 | 690篇 |
2022年 | 387篇 |
2021年 | 802篇 |
2020年 | 1102篇 |
2019年 | 775篇 |
2018年 | 1262篇 |
2017年 | 1106篇 |
2016年 | 1321篇 |
2015年 | 1261篇 |
2014年 | 1721篇 |
2013年 | 2118篇 |
2012年 | 1923篇 |
2011年 | 1962篇 |
2010年 | 1490篇 |
2009年 | 1604篇 |
2008年 | 1699篇 |
2007年 | 1707篇 |
2006年 | 1729篇 |
2005年 | 1550篇 |
2004年 | 1365篇 |
2003年 | 1312篇 |
2002年 | 1239篇 |
2001年 | 975篇 |
2000年 | 947篇 |
1999年 | 897篇 |
1998年 | 568篇 |
1997年 | 534篇 |
1996年 | 580篇 |
1995年 | 557篇 |
1994年 | 428篇 |
1993年 | 358篇 |
1992年 | 686篇 |
1991年 | 685篇 |
1990年 | 619篇 |
1989年 | 661篇 |
1988年 | 587篇 |
1987年 | 579篇 |
1986年 | 544篇 |
1985年 | 499篇 |
1984年 | 452篇 |
1983年 | 373篇 |
1982年 | 313篇 |
1981年 | 248篇 |
1979年 | 329篇 |
1978年 | 329篇 |
1977年 | 249篇 |
1976年 | 237篇 |
1975年 | 244篇 |
1974年 | 245篇 |
1972年 | 238篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
3.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
4.
5.
6.
7.
Caroline Williamsson Jenny Rystedt Bodil Andersson 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2021,23(6):847-853
BackgroundLittle is known of possible gender differences in treatment of periampullary tumours and outcome after pancreatoduodenectomy (PD), and the aim of this study was therefore to investigate any variances from national multicentre perspective.MethodsData from the Swedish National Registry for Pancreatic and Periampullary Cancer for all patients diagnosed with a periampullary tumour from 2012 throughout 2017 was collected. The material was analysed in two groups, men and women, for palliative treatment and curative intended resection.ResultsA total of 5677 patients were included, 2906 (51%) men and 2771 (49%) women. Women were older than men, 72 (65–78) years vs. 70 (64–76), p < 0.001. A lesser proportion of women were planned for resection (1131 (41%) vs. 1288 (44%), p = 0.008), but after adjusting for age and tumour location no difference was seen. Postoperative morbidity was equal, but women had significantly better long-term survival than men. The survival was equal for palliative men and women.ConclusionNo gender bias could be established when analysing treatment for periampullary tumours in Sweden, even though less women were offered surgery. Data suggest that even though women were older they tolerate surgery well and hence offering PD at a higher age for women could be suggested. 相似文献
8.
9.
10.